HTA trials will no longer infringe UK patent law
This article was originally published in Scrip
A legal obstacle to the conduct of clinical trials in the UK should be removed by October 1, if recommendations from the UK government are followed. The UK’s narrow interpretation of the research exceptions to the 1977 UK Patents Act had meant that companies conducting comparative clinical research in the UK were open to prosecution for patent infringement. The government has now recommended a broader interpretation of the exceptions that aligns the UK with other major European nations and, according to industry associations, promises to make the UK a more attractive venue for comparative trials.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.